# Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPV

> **NCT03310073** · PHASE4 · COMPLETED · sponsor: **PT Bio Farma** · enrollment: 143 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** bOPV
- **BIOLOGICAL:** Pentabio
- **BIOLOGICAL:** IPV

## Key facts

- **NCT ID:** NCT03310073
- **Lead sponsor:** PT Bio Farma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2017-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03310073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03310073, "Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPV". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03310073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*